logo
Plus   Neg
Share
Email

Biogen To Gain Rights To BAT1806 From Bio-Thera - Quick Facts

Biogen Inc. (BIIB) and Bio-Thera Solutions have reached an agreement to develop, manufacture and commercialize BAT1806, a phase 3 clinical stage anti-interleukin-6 receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA (tocilizumab). Biogen will gain exclusive regulatory, manufacturing and commercial rights to BAT1806 in all countries excluding China.

Biogen will make an upfront payment of $30 million to Bio-Thera Solutions, contingent upon Bio-Thera Solutions' phase 3 for BAT1806 achieving satisfactory results. Bio-Thera Solutions will be eligible to receive potential milestone payments on achieving commercial milestones. Biogen will also pay Bio-Thera Solutions tiered royalties.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Nasdaq Inc. (NDAQ) reported Wednesday that its net income for the first quarter grew to $298 million or $1.78 per share from $203 million or $1.22 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $327 million or $1.96 per share, compared to $251 million... Guan's Mushroom Co. is recalling all cases of its 200g/7.05-ounce packages of Enoki Mushroom citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recalled Enoki is a product of China and comes in a clear plastic package with the description "Enoki Mushroom" in English, Korean and French, and Guan's logo in the front. Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to grow
Follow RTT